Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Alessandro Di Federico, Ilaria Ricciotti, Valentina Favorito, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 9, pp. 1017-1029
Closed Access | Times Cited: 22

Showing 22 citing articles:

Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Giulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo
Cancer Research (2024) Vol. 84, Iss. 8, pp. 1199-1209
Open Access | Times Cited: 12
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
KRASG12D drives immunosuppression in lung adenocarcinoma through paracrine signaling
Emily L Lasse-Opsahl, Ivana Barravecchia, Elyse McLintock, et al.
JCI Insight (2025) Vol. 10, Iss. 1
Open Access
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
Linyan Tian, Chengming Liu, Sufei Zheng, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Chaperone Directed Heterobifunctional Molecules Circumvent Krasg12c Inhibitor Resistance
Takeshi Shimamura, Inés Pulido, Qiyue Luan, et al.
(2025)
Closed Access
A clinician’s perspective: what tumor-organoid researchers ought to know
Jeong Uk Lim
Organoid (2025) Vol. 5, pp. e1-e1
Open Access
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
Second-line therapy for KRAS-positive metastatic non-small cell lung cancer
Martin Svatoň
Onkologie (2025) Vol. 19, Iss. 1, pp. 29-32
Closed Access
Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
H. Y. Shin, S. O. Hwang, Jeong Hyun Jeong, et al.
Pharmacological Research (2025), pp. 107722-107722
Open Access
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.
Inés Pulido, Qiyue Luan, Sara Pastor-Puente, et al.
Cancer Letters (2025), pp. 217691-217691
Open Access
Design, synthesis, and evaluation of purine and pyrimidine-based KRAS G12D inhibitors: Towards potential anticancer therapy
S.L. Park, Venu Venkatarame Gowda Saralamma, Sagar D. Nale, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28495-e28495
Open Access | Times Cited: 2
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Katherina Bernadette Sreter, Maria Joana Catarata, Maximilian von Laffert, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96
Randa Mahran, Jonas N. Kapp, Salla Valtonen, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 10, pp. 2152-2164
Closed Access | Times Cited: 2
The Triterpenoid CDDO-Methyl Ester Reduces Tumor Burden, Reprograms the Immune Microenvironment, and Protects from Chemotherapy-Induced Toxicity in a Preclinical Mouse Model of Established Lung Cancer
Jessica A. Moerland, Karen T. Liby
Antioxidants (2024) Vol. 13, Iss. 6, pp. 621-621
Open Access | Times Cited: 1
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Ateş Kutay Tenekeci, A. Unal, Furkan Ceylan, et al.
Future Oncology (2024) Vol. 20, Iss. 37, pp. 3019-3038
Closed Access | Times Cited: 1
KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
Samantha L. Tinsley, Ella Rose D. Chianis, Rebecca A. Shelley, et al.
Oncogene (2024)
Closed Access | Times Cited: 1
WITHDRAWN: Oncogenic KRASG12Dextrinsically induces an immunosuppressive microenvironment in lung adenocarcinoma
Emily L Lasse-Opsahl, Rachael K. Baliira, Ivana Barravecchia, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies
Cong Ding, Gaoyuan Wang, Wenqing Zou, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-11
Closed Access
KRAS inhibitors in drug resistance and potential for combination therapy
Lala S. Rathod, Nikhil S. Sakle, Santosh N. Mokale
Tumori Journal (2024)
Closed Access
Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring
Michele Tomanelli, Federica Guffanti, Giulia Vargiu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability
Sílvia Casacuberta‐Serra, Í. González-Larreategui, Laura Soucek
Translational Lung Cancer Research (2023) Vol. 12, Iss. 12, pp. 2570-2575
Open Access | Times Cited: 1
KRAS-Degrading Compounds: A Novel Approach to Treat Cancer by Targeting Both Wild-Type and Mutated KRAS Forms
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 11, pp. 1493-1495
Closed Access
KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
Samantha L. Tinsley, Rebecca A. Shelley, G. Mall, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top